Details

Autor(en) / Beteiligte

• Komatsu, Takaaki
• Katsuyama, Soh
• Mizoguchi, Hirokazu
• Sakurada, Chikai
• Tsuzuki, Minoru
• Sakurada, Shinobu
• Sakurada, Tsukasa

Titel

Spinal ERK2 activation through δ2-opioid receptors contributes to nociceptive behavior induced by intrathecal injection of leucine-enkephalin

Ist Teil von

• Peptides (New York, N.Y. : 1980), 2014-04, Vol.54, p.131-139

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• •Nociceptive behavior was not observed in mice treated with i.t. Leu-ENK alone.•Leu-ENK co-injected with peptidase inhibitors evoked nociceptive behaviors.•Leu-ENK co-injected with peptidase inhibitors evoked activation of spinal ERK2.•The nociceptive behavioral response was evoked through spinal δ2-opioid receptor. Intrathecal (i.t.) injection of leucine-enkephalin (Leu-ENK), co-administered with peptidase inhibitors, phosphoramidon (an endopeptidase 24.11 inhibitor), and bestatin (a general aminopeptidase inhibitor), produced behaviors consisting of the biting and/or licking of the hindpaw and the tail along with hindlimb scratching directed toward the flank, which peaked at 10–15min after an injection. This characteristic behavior was not observed in mice treated with i.t. Leu-ENK alone. We also investigated the effect of the extracellular signal-regulated kinase (ERK) in spinal processing of nociception induced by i.t. co-administration of Leu-ENK with phospharamidon and bestatin. Western blot analysis of phospho-ERK (pERK) showed a significant increase of pERK2 in the lumbar spinal cord in response to i.t. Leu-ENK co-injected with peptidase inhibitors. The MAP kinase-ERK inhibitor, U0126 dose-dependently attenuated the nociceptive behavior and spinal ERK activation to i.t. Leu-ENK co-injected with peptidase inhibitors. Furthermore, the nociceptive behavior and spinal ERK activation evoked by i.t. Leu-ENK in combination with peptidase inhibitors were inhibited by co-administration of the non-selective δ-opioid receptor antagonist, naltrindole, the selective δ2-opioid receptor antagonist, naltriben, the non-competitive N-methyl-d-aspartate (NMDA) antagonist, MK-801 or the non-selective nitric oxide synthase inhibitor, l-NAME, the selective nNOS inhibitor, Nω-propyl-l-arginine or the selective iNOS inhibitor, W1400, but not by the selective δ1-receptor antagonist, BNTX (7-benzylidenenaltrexone). These results suggest that spontaneous nociceptive behaviors produced by i.t. co-administration of Leu-ENK with peptidase inhibitors may be induced by an activation of the glutamate-NO-ERK pathway through the δ2-opioid receptor in the dorsal spinal cord.